Literature DB >> 2917320

Gangliosides of human melanoma.

T Tsuchida1, R E Saxton, D L Morton, R F Irie.   

Abstract

Human melanoma synthesizes a large quantity of gangliosides, glycosphingolipids containing sialic acid. The authors previously have demonstrated that the ganglioside profile differs among individual melanomas and is widely heterogeneous. In the current study, a retrospective study was performed to compare the relationship between the quantity of five major gangliosides of human melanoma (GM3, GM2, GD3, GD2, and alkali-labile ganglioside) and nine clinical factors (sex, age, site, stage, tumor size, pigmentation, histopathologic type of primary tumor, chemosensitivity, and prognosis). Melanoma specimens studied were obtained from patients of our clinic and included 52 biopsy specimens and 28 cultured cell lines. Analysis of melanoma biopsy specimens have shown a differential ganglioside expression among different sites of tumor, pigmentation, and histopathologic types. Results of cultured melanoma cell lines differed from those of biopsy specimens, but ganglioside expression also differed among the site of tumor, tumor size, histopathologic types, and chemosensitivity. GM3 positively correlated with a good prognosis in both biopsy and cultured melanomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917320     DOI: 10.1002/1097-0142(19890315)63:6<1166::aid-cncr2820630621>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.

Authors:  Xiaohong Wu; Govind Ragupathi; Katherine Panageas; Feng Hong; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

Review 2.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

3.  Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.

Authors:  Annette Compter; Willem Boogerd; Johannes V van Thienen; Dieta Brandsma
Journal:  Neurol Clin Pract       Date:  2017-10

4.  Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.

Authors:  D S Hoon; C T Kuo; S Wen; H Wang; L Metelitsa; C P Reynolds; R C Seeger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  An improved method for the measurement of total lipid-bound sialic acids after cleavage of alpha 2,8 sialic acid linkage with Vibrio cholerae sialidase in the presence of cholic acid, SDS and Ca2+.

Authors:  M A Maliakal; M H Ravindranath; R F Irie; D L Morton
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

Review 6.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

7.  Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Authors:  Sojun Hoshimoto; Tatsushi Shingai; Donald L Morton; Christine Kuo; Mark B Faries; Kelly Chong; David Elashoff; He-Jing Wang; Robert M Elashoff; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

8.  Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

Authors:  José-Alberto Palma; Salvador Martín-Algarra
Journal:  J Neurooncol       Date:  2009-03-06       Impact factor: 4.130

9.  Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Authors:  Chun-Yen Tsao; Francesco Sabbatino; Nai-Kong V Cheung; Jeff Chi-Feng Hsu; Vincenzo Villani; Xinhui Wang; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

10.  Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.

Authors:  Eric Yvon; Michele Del Vecchio; Barbara Savoldo; Valentina Hoyos; Aurélie Dutour; Andrea Anichini; Gianpietro Dotti; Malcolm K Brenner
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.